Last10K.com

Celgene Corp (CELG) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Celgene Corp

CIK: 816284 Ticker: CELG

Exhibit 99.1

 

 

CELGENE REPORTS THIRD QUARTER 2018

OPERATING AND FINANCIAL RESULTS

 

–    Total net product sales of $3,890 million, increased 18% Y/Y

 

–    Raising full-year total revenue guidance to ~$15.2 billion and OTEZLA® net product sales to ~$1.6 billion

 

–    Showcasing our next-generation pipeline across multiple disease areas at ASH

 

–    Appointed Dr. Alise Reicin as President of Global Clinical Development

 

SUMMIT, NJ — (October 25, 2018) — Celgene Corporation (NASDAQ: CELG) reported net product sales of $3,890 million for the third quarter of 2018, an 18 percent increase from the same period in 2017. Celgene reported third quarter 2018 total revenue of $3,892 million, an 18 percent increase compared to $3,287 million in the third quarter of 2017.

 

Based on U.S. GAAP (Generally Accepted Accounting Principles), Celgene reported net income of $1,082 million and diluted earnings per share (EPS) of $1.50 for the third quarter of 2018. For the third quarter of 2017, GAAP net income was $988 million and diluted EPS was $1.21.

 

Adjusted net income for the third quarter of 2018 increased 6 percent to $1,645 million compared to $1,555 million in the third quarter of 2017. For the same period, adjusted diluted EPS increased 20 percent to $2.29 from $1.91.

 

“Excellent top- and bottom-line momentum in the third quarter supports raising our 2018 financial guidance,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene Corporation. “We are focused on shaping Celgene’s future by rapidly advancing our late-stage pipeline, accelerating promising early research programs, and strengthening the organization.”

 

Third Quarter 2018 Financial Highlights

 

Unless otherwise stated, all comparisons are for the third quarter of 2018 compared to the third quarter of 2017. The adjusted operating expense categories presented below exclude share-based employee compensation expense and collaboration-related upfront expense. Please see the attached Use of Non-GAAP Financial Measures and Reconciliation of GAAP to Adjusted Net Income for further information relevant to the interpretation of adjusted financial measures and

 


The following information was filed by Celgene Corp (CELG) on Thursday, October 25, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Celgene Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Celgene Corp.

Continue

Assess how Celgene Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Celgene Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Shares
Expense
Cash Flow
Debt
Product
Geography
Income
Other
Inside Celgene Corp's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Income
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive (Loss) Income (Components Of Aoci) (Details)
Accumulated Other Comprehensive (Loss) Income (Narrative) (Details)
Accumulated Other Comprehensive (Loss) Income (Reclassification Of Aoci) (Details)
Accumulated Other Comprehensive (Loss) Income (Tables)
Acquisitions And Divestitures
Acquisitions And Divestitures (Delinia) (Details)
Acquisitions And Divestitures (Impact Biomedicines) (Details)
Acquisitions And Divestitures (Juno - Income Statement Location) (Details)
Acquisitions And Divestitures (Juno Therapeutics - Narrative) (Details)
Acquisitions And Divestitures (Juno) (Details)
Acquisitions And Divestitures (Juno- Pro Forma) (Details)
Acquisitions And Divestitures (Other Acquisitions) (Details)
Acquisitions And Divestitures (Tables)
Cash, Cash Equivalents, Debt Securities Available-For-Sale And Equity Investments With Readily Determinable Fair Values
Cash, Cash Equivalents, Debt Securities Available-For-Sale And Equity Investments With Readily Determinable Fair Values (Duration Periods) (Details)
Cash, Cash Equivalents, Debt Securities Available-For-Sale And Equity Investments With Readily Determinable Fair Values (Narrative) (Details)
Cash, Cash Equivalents, Debt Securities Available-For-Sale And Equity Investments With Readily Determinable Fair Values (Schedule Of Available-For-Sale Reconciliation) (Details)
Cash, Cash Equivalents, Debt Securities Available-For-Sale And Equity Investments With Readily Determinable Fair Values (Tables)
Collaboration Agreements
Collaboration Agreements (Details)
Collaboration Agreements (Period End Balances) (Details)
Collaboration Agreements (Schedule Of Collaboration Agreements) (Details)
Collaboration Agreements (Tables)
Commitments And Contingencies
Debt
Debt (Narrative) (Details)
Debt (Senior Notes Carrying Values) (Details)
Debt (Short-Term Borrowings And Current Portion Of Long-Term Debt) (Details)
Debt (Tables)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Cumulative Basis Adjustments For Fair Value Hedges) (Details)
Derivative Instruments And Hedging Activities (Fair Value And Presentation In The Balance Sheet) (Details)
Derivative Instruments And Hedging Activities (Foreign Currency Forward Contracts) (Details)
Derivative Instruments And Hedging Activities (Foreign Currency Option Contracts) (Details)
Derivative Instruments And Hedging Activities (Interest Rate Swap Contracts) (Details)
Derivative Instruments And Hedging Activities (Location And Amount Of Gain Or (Loss) Recognized In Income On Fair Value And Cash Flow Hedging Relationships) (Details)
Derivative Instruments And Hedging Activities (Narrative) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Impacts On Income) (Details)
Derivative Instruments And Hedging Activities (Tables)
Earnings Per Share
Earnings Per Share (Narrative) (Details)
Earnings Per Share (Schedule Of Earnings Per Share) (Details)
Earnings Per Share (Tables)
Financial Instruments And Fair Value Measurement
Financial Instruments And Fair Value Measurement (Assumption Calculations) (Details)
Financial Instruments And Fair Value Measurement (Level 3 Fair Value Roll-Forward) (Details)
Financial Instruments And Fair Value Measurement (Measurement Inputs) (Details)
Financial Instruments And Fair Value Measurement (Narrative) (Details)
Financial Instruments And Fair Value Measurement (Schedule Of Remeasurement Of Equity Investments) (Details)
Financial Instruments And Fair Value Measurement (Tables)
Income Taxes
Income Taxes (Details)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (Narrative) (Details)
Intangible Assets And Goodwill (Summary Of Intangible Assets) (Details)
Intangible Assets And Goodwill (Tables)
Inventory
Inventory (Details)
Inventory (Tables)
Legal Proceedings
Legal Proceedings (Narrative) (Details)
Nature Of Business, Basis Of Presentation And New Accounting Standards
Nature Of Business, Basis Of Presentation And New Accounting Standards (Asu 2017-12) (Details)
Nature Of Business, Basis Of Presentation And New Accounting Standards (Cumulative Effect Adjustments) (Details)
Nature Of Business, Basis Of Presentation And New Accounting Standards (Equity Investments, Asu 2016-01) (Details)
Nature Of Business, Basis Of Presentation And New Accounting Standards (Narrative) (Details)
Nature Of Business, Basis Of Presentation And New Accounting Standards (Newly Adopted Standards) (Details)
Nature Of Business, Basis Of Presentation And New Accounting Standards (Not Yet Adopted) (Details)
Nature Of Business, Basis Of Presentation And New Accounting Standards (Policies)
Nature Of Business, Basis Of Presentation And New Accounting Standards (Tables)
Revenue
Revenue (Details)
Revenue (Gross Product Sales To Net Product Sales Reconciliation) (Details)
Revenue (Narrative) (Details)
Revenue (Tables)
Share-Based Compensation
Share-Based Compensation (Components Of Share-Based Compensation Expense) (Details)
Share-Based Compensation (Narrative) (Details)
Share-Based Compensation (Summary Of Stock Options, Rsus And Psus) (Details)
Share-Based Compensation (Tables)
Share-Based Compensation (Unvested Awards And Weighted-Average Periods) (Details)

Material Contracts, Statements, Certifications & more

Celgene Corp provided additional information to their SEC Filing as exhibits

Ticker: CELG
CIK: 816284
Form Type: 10-Q Quarterly Report
Accession Number: 0000816284-18-000024
Submitted to the SEC: Thu Oct 25 2018 1:10:51 PM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Sunday, September 30, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/celg/0000816284-18-000024.htm